Lumos Diagnostics (ASX:LDX) has received confirmation of Medicare reimbursement coverage from an additional Medicare Administrative Contractor, CGS Administrators.
Lumos says its point-of-care diagnostic FebriDx will be included in the Medicare Fee Schedule of CGS. CGS is responsible for managing Medicare payments in Kentucky and Ohio.
Lumos says that with the addition of CGS to the previously announced coverage from Novitas and Palmetto, First Coast Service Options, Noridian Healthcare Solutions, and WPS Health Solutions, it has Medicare reimbursement from six of the seven administrative contractors, representing over 85 per cent of the total US Medicare payment coverage.
Medicare represents approximately 20 to 24 per cent of the US payor mix and often sets a precedent for private payors.
Lumos managing director Doug Ward said, “Securing additional Medicare coverage from CGS for FebriDx reinforces our commitment to developing a point-of-care diagnostic solution that not only benefits patients, but also integrates seamlessly into care pathways and delivers value to the broader health system.”
“Lumos remains committed to securing adoption from the remaining MAC, NGS, and pursuing reimbursement coverage from private payors, with the goal of achieving nationwide access for patients and supporting broad clinical adoption of FebriDx.”
